People
Foster City, Calif.-based Gilead Sciences reorganized some of its executive leadership team after it was announced that Chief Medical Officer Andrew Cheng is leaving the company to pursue other opportunities.
A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer. This morning Sigilon announced Bioverativ veteran Rogerio Vivaldi will helm the Cambridge, Mass.-based company.
Acorda Therapeutics Chief Technology Officer Rick Batycky is leaving the company to take over the helm of an unnamed biotechnology company.
As Novartis wrangles with the fallout from its association with Michael Cohen and the fees it paid his consulting company for access to the administration of President Donald Trump, the Swiss pharma giant has brought on a new chief ethics officer.
GSK’s Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let’s take a look at some of those!
Shares of struggling OvaScience have dipped 8 percent this morning after the company announced it entered into an all-stock reverse merger agreement with privately-held Millendo Therapeutics, Inc. of Ann Arbor, Mich.
The pharma industry has developed ad campaigns to tout the efficacy of its branded products to consumers, often using celebrities to add his or her personal stamp onto a pharmaceutical product.
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Addressing the high cost of prescription medications will continue to be a hot-button issue as stakeholders in the industry grapple with consumer and political pressures to lower the list cost of many life-saving drugs. Dean Erhardt, chief executive officer of D2 Consulting, is floating an idea that could offer a solution to pricing concerns.
On Monday, the U.S. Food and Drug Administration issued a new draft guidance for the development of novel medicines aimed at the treatment of opioid use disorder.
PRESS RELEASES